Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug in ATTR Amyloidosis with Cardiomyopathy
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
Precious Metals & Critical Minerals Virtual Investor Conference Presentations Now Available for On-Demand Viewing
CoTec Holdings Corp. Announces Final Closing of Private Placement of Unsecured Convertible Debentures, Total Raise of $20 Million
